Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:5:393-6.
doi: 10.2147/OPTH.S17527. Epub 2011 Mar 22.

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Kenji Inoue  1 , Mieko Masumoto, Masato Wakakura, Goji Tomita
Affiliations

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months

Kenji Inoue et al. Clin Ophthalmol. 2011.

Abstract

Purpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost.

Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period.

Results: The mean baseline IOP was 17.2 ± 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 ± 3.0 mmHg, 14.5 ± 3.2 mmHg, and 14.6 ± 2.6 mmHg respectively (P < 0.0001, 1-β(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions.

Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.

Keywords: dorzolamide; latanoprost; primary open-angle glaucoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Intraocular pressure (IOP) before and after addition of dorzolamide. Notes: *P < 0.0001, ANOVA and the Bonferroni/Dunnett tests.
Figure 2
Figure 2
Mean deviation at baseline and 12 months after addition of dorzolamide. Note: Paired t-test. Abbreviation: NS, not significant.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Van der Valk R, Webers CA, Jan SA, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs. Ophthalmology. 2005;112:1177–1185. - PubMed
    1. Araie M, Abe H. The Japan Glaucoma Society Guidelines for Glaucoma, 2nd ed. Jpn J Ophthalmol Soc. 2006;110:777–814.
    1. Araie M, Kitazawa Y, Azuma I, et al. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical anti-glaucoma agents. J Ocul Pharmacol Ther. 2003;19:517–525. - PubMed
    1. Nakamura Y, Ishikawa S, Nakamura Y, et al. 24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost. Clin Ophthalmol. 2009;3:395–400. - PMC - PubMed
    1. Maruyama K, Shirato S. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma. A prospective randomized crossover trial. J Glaucoma. 2006;15:341–345. - PubMed

LinkOut - more resources